Discover the promising final report on the effectiveness of a novel combination therapy using Carfilzomib, Thalidomide, and Dexamethasone in the battle against relapsed and refractory multiple myeloma.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.
Ninkovic et al., Haematologica 2024
DOI: 10.3324/haematol.2023.284238
Listen up, folks, we’ve got something huge here!
We’ve done an incredible study, the best, with the Australian Lymphoma and Leukaemia Group and the Asian Myeloma Network. We’re talking about a treatment for multiple myeloma that’s really making a difference. It’s called KTd – that’s carfilzomib, thalidomide, and dexamethasone. And let me tell you, it’s fantastic.
We gave it to patients who had this disease before, and it worked like a charm. They took it for 18 months, and the results – amazing. We’re seeing a median progression-free survival of 22.3 months. That’s nearly two years, folks! And the overall survival rate? It’s through the roof – 73.8% at two years. Believe me, that’s big.
And the response rate? An unbelievable 88%. People are responding to this treatment, and they’re doing great. Plus, it doesn’t matter if they’re from Asia or not, which is very important. Everyone’s getting the same top-notch results.
Now, let’s talk safety. This KTd, it’s safe. It’s got a profile that’s just what we expected. No surprises. And it’s not just effective, it’s tolerable. People can handle it, which is so important.
So, what’s the bottom line? KTd is a winner. It’s a game-changer for people with relapsed multiple myeloma. And it’s a great option when other treatments are too expensive or not available. We’re doing great things here, and KTd is proof of that. It’s just the best, folks.